Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
We introduce the clinical development context of novel therapies for rare diseases. Areas of research progress are highlighted such as chronic myeloid leukemia and cystic fibrosis. Huntington's disease is given as an example of the many areas in which more progress is needed. Regulatory definitions of rare diseases are given. Key aspects of the setting include the genetic origin of many diseases, potential lack of clinical understanding of the diseases, a pediatric focus, funding challenges, regulatory uncertainties, privacy considerations, and difficulties identifying appropriate patients for study. A non-technical focus on quantitative issues such as statistics is brought to the forefront.